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Abstract
Background: Obstructive sleep apnea (OSA) is associated with an increase in the prevalence and incidence
of hypertension and cardiovascular diseases. Data about epidemiological characteristics of OSA in Chinese
hypertensive populations is limited.
Methods: Hypertensive subjects without a prior diagnosis of OSA were recruited, and the apnea-hyponea index
(AHI) was assessed by polysomnography. Comparisons were performed between subjects without OSA and with
different degrees of OSA. Gender-specific differences in epidemiological characteristics of OSA were also analyzed.
Univariate and multivariate regression analyses were conducted to evaluate the associations between OSA and
other variables.
Results: A total of 971 hypertensive subjects were enrolled and 685 (70.5%) were diagnosed with OSA. Compared
to those without OSA, subjects with OSA were more likely male (78.4% versus 71.7%, P = 0.016) and at higher
cardiovascular risk in subjects with moderate-severe OSA. Among the 685 OSA subjects, 79.4% (537 cases) were
males. Gender-specific differences in epidemiological characteristics of OSA were observed. Multivariate regression
analyses revealed that after adjusting for covariates, only body mass index positively correlated with OSA in males
(odds ratio (OR): 1.064, 95% confidence interval (CI): 1.008–1.123, P = 0.024). In female subjects, after adjusting for
covariates, only age positively correlated with OSA (OR: 1.071, 95% CI: 1.029–1.116, P = 0.001).
Conclusion: In summary, in a Chinese hypertensive population, OSA prevalence is strikingly high. Hypertensive
subjects with the most severe OSA are at greater cardiovascular risk. There are significant differences in
epidemiological characteristics of OSA between male and female.
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Background
Obstructive sleep apnea (OSA) is a major public health
problem worldwide, and is associated with an increase
in the prevalence and incidence of arterial hypertension
and cardiovascular diseases (CVD) [1, 2]. Repetitive
obstructive apneas appear to initiate a variety of patho-
physiological effects which subsequently act to promote
and accelerate the development of CVD [3–5]. A number
of markers associated with OSA have been identified, and
male gender is considered to be a major independent risk
factor [6]. Data from population-based studies reveal that
compared to females, the prevalence of OSA in males is
1.5 to 3 times greater, and in undiagnosed OSA patients,
the ratio of males to females was nearly 2:1 [7–9]. These
data strongly suggest OSA has a male predilection. Never-
theless, these findings may also indirectly reflect a relative
lack of awareness and consequent under-evaluation of
OSA in females [9]. Furthermore, it has been reported
that female OSA patients may have greater improvement
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in cardiovascular function than their male counterparts
with appropriate treatment [10]. These data collectively
indicate the clinical importance of promoting awareness
of OSA in females. They further underscore that a better
understanding of the differences in epidemiological char-
acteristics between male and female OSA populations is
also a top priority.
In recent decades, the prevalence of arterial hyperten-
sion, a frequent co-morbidity of OSA, has increased,
likely as a consequence of the increased prevalence of
OSA. However, thus far, evidence regarding epidemio-
logical characteristics of OSA in Chinese populations is
limited. Moreover, whether there are gender-specific dif-
ferences in clinical features of OSA is also unknown in
the Chinese populations. We hypothesized that the
prevalence of OSA might be positively related to in-
creased prevalence of hypertension and gender-specific
differences of OSA characteristics might also exist. In
order to demonstrate our hypotheses, we therefore
conducted a cross-sectional study to investigate the
prevalence and epidemiological characteristics of OSA in
randomly selected hypertensive patients in our inpatient
department. We further investigated the differences in
epidemiological characteristics of OSA between male
and female hypertensive subjects. Hopefully, our present
research will provide basis for the cohort and inter-




This study was approved by the clinical research ethics
committee of Guangdong General Hospital (No. GDREC
2015373H), and informed consent was obtained before
participants were enrolled. Included criteria were as fol-
lows: previous diagnosis of essential hypertension and
had not been previously diagnosed with OSA. Excluded
criteria were as follows: pre-hypertensive stage or docu-
mented secondary hypertension, or had a history of
OSA or treatment with continuous positive airway pres-
sure or devices. Polysomnography (PSG) was performed
to evaluate the apnea-hypopnea index (AHI). All partici-
pants had been informed the detailed procedures of
PSG. Participants were allowed to have their regular
sleep-wake rhythm, while substances such as alcohol or
sleeping medicines were not allowed to take during PSG
performance. In brief, if the patients had airflow
complete blockage for more than 10 s or > 50% reduc-
tion in respiratory airflow accompanying > 3% reduction
in SaO2 for more than 10 s, the apnea or hypopnea
events would be recorded. In brief, on the basis of AHI
as defined by the total number of apneas and hypopneas
per sleep hour based on current AASM guidelines. Par-
ticipants with AHI of 5–14 were defined as mild OSA,
15–29 were moderate and 30 or more were severe. Less
than 5 were considered without OSA. All measurements
were assessed by using PHILIPS RESPIRONICS Alice
PDx and the validity and reliability of this device and
measures had been broadly demonstrated our previous
study [11].
Clinical and laboratory data collection
Clinical data including demographics, anthropometrics,
previous medical history and medicine usage were re-
corded on a clinical report form by two investigators
and underwent re-checks by two additional investigators.
Fasting venous blood was sampled for measurements of
lipid profiles, fasting plasma glucose (FPG) and glycated
hemoglobin (HbA1c). Echocardiography was used to
evaluate thickness of the inter-ventricular septum (IVS)
and left ventricular posterior wall (LVPW).
Study design
This was a cross-sectional single-center study. Initially,
all participants were separated into those with OSA and
those without OSA, and comparisons were performed.
Thereafter, all participants were divided into 3 groups,
namely without OSA, mild OSA, and moderate-severe
OSA groups, and clinical characteristics of these three
groups were evaluated and compared. Participants with
OSA were then separated into male and female groups,
and between-group differences were analyzed. Last, uni-
variate and multivariate regression analyses were con-
ducted to analyze and compare the associations between
OSA and other clinical variables in the male and female
populations, respectively.
Statistical analysis
Standard descriptive statistics were in the analysis. Con-
tinuous variables were described using mean and SD.
Categorical variables were described by the percentages
of categories. The statistical significance of differences is
analyzed using one-way ANOVA or Mann–Whitney U
test for continuous variables and the chi-square or
Fisher exact test for categorical variables. Univariate and
multivariate regression analyses were used to evaluate
the association between OSA and clinical and laboratory
variables. Statistical analyze were computed using SPSS
18.0 (SPSS Inc, Chicago, IL). All statistical tests were




A total of 971 hypertensive subjects were enrolled,
76.4% of whom were male. Among these 971 subjects,
70% were diagnosed with OSA. Comparisons were
performed between subjects with and without OSA.
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Compared to subjects without OSA, those with OSA
were older, more likely males and had higher body mass
index (BMI), IVS, LVPW and HbA1c (P < 0.05 for all
comparisons) (Table 1). Notably, compared to those
without OSA, subjects with OSA appeared to be at
higher cardiovascular risk as reflected by higher
prevalence of proteinuria, diabetes mellitus, dyslipidemia,
aneurysm, coronary heart disease (CHD), cerebrovascular
disease, heart failure, atrial fibrillation and hypertrophic
cardiomyopathy (HCM), though these between-group dif-
ferences did not achieve statistical significance. With re-
spect to medications, only statin and beta-blocker usage
were significantly higher in the OSA group (P < 0.05); no
significant differences in other medications were observed.
Comparisons between OSA groups
Epidemiological characteristics of subjects with different
degrees of OSA were compared. As shown in Table 2,
compared to the mild OSA group, subjects in the
moderate-severe OSA group were more likely males,
had higher values of BMI, IVS, LVPW and creatinine,
and significantly higher prevalence of proteinuria,
diabetes mellitus and heart failure (P < 0.05 for all
comparisons). In addition, dyslipidemia, aneurysm, CHD
and HCM tended to be more frequent in the moderate-
severe OSA group, although without statistical signifi-
cance, indicating a relation between OSA severity and
cardiovascular risk.
Comparison between male and female OSA patients
Among 685 OSA patients, males were predominant
(79% (537 cases)). Compared to male OSA patients
(Table 3), females were older, had higher plasma levels
of HbA1c, FPG and TC, and higher likelihood of dia-
betes mellitus and dyslipidemia (P < 0.05). Nonetheless,
male OSA patients had higher values of AHI, IVS,
LVPW and creatinine (P < 0.05). In addition, aortic dis-
section and aneurysm were also significantly higher in
male OSA subjects (P < 0.05). Notably, except for CHD,
cerebrovascular disease, heart failure, atrial fibrillation
and HCM tended to be more frequent in females though
without statistical significance. No significant differences
in medications and other clinical and laboratory
variables were observed between the male and female
OSA patients.
Univariate and multivariate regression analyses
The 971 participants were separated into two groups,
namely with OSA and without OSA. In the univariate re-
gression analysis, as shown in Table 4, age, BMI, HbA1c,
IVS, IVPW, statins, beta-blockers and uric acid were posi-
tively associated with OSA, whereas HDL-C was nega-
tively associated with OSA. We further evaluated the
gender-specific differences in risk factors associated with
OSA. In the male subjects, as shown in Table 5, after
adjusting for potential covariates, only BMI remained
positively correlated with OSA (odds ratio (OR): 1.064,
95% confidence interval (CI): 1.008–1.123, P = 0.024). In
the female subjects (Table 6), after adjusting for potential
Table 1 Patient characteristics
Variables Without OSA With OSA P value
N (%) 286 (29.5) 685 (70.5)
Age (years) 56.5 ± 13.3 59.3 ± 11.7 0.001
Male (%) 71.7 78.4 0.016
BMI (Kg/m2) 24.6 ± 3.6 25.8 ± 4.1 <0.001
SBP (mm Hg) 137.3 ± 20.4 137.4 ± 21.5 0.975
DBP (mm Hg) 79.3 ± 13.6 79.4 ± 14.3 0.926
AHI 1.7 ± 1.4 22.0 ± 16.7 0.001
IVS (mm) 10.7 ± 1.8 11.4 ± 2.3 <0.001
LVPW (mm) 10.2 ± 1.8 10.5 ± 1.8 0.007
HbA1c (%) 6.1 ± 1.1 6.3 ± 1.2 0.029
Creatinine (μmol/L) 91.6 ± 48.0 99.0 ± 65.9 0.098
BUN (mmol/L) 5.5 ± 3.2 5.8 ± 2.8 0.162
FPG (mmol/L) 6.2 ± 2.6 6.5 ± 3.0 0.130
Triglyceride (mmol/L) 1.9 ± 0.3 1.8 ± 0.1 0.582
Total cholesterol (mmol/L) 4.5 ± 1.3 4.5 ± 1.2 0.643
LDL-C (mmol/L) 2.7 ± 1.0 2.7 ± 1.0 0.939
HDL-C (mmol/L) 1.0 ± 0.3 1.0 ± 0.2 0.961
Proteinuria (%) 17.1 20.4 0.183
Diabetes mellitus (%) 19.6 24.4 0.061
Dyslipidemia (%) 10.5 14.6 0.052
Aortic dissection (%) 20.3 19.9 0.472
Aneurysm (%) 4.5 5.4 0.354
CHD (%) 37.4 41.9 0.110
Cerebrovascular disease (%) 6.6 9.9 0.063
Heart failure (%) 19.2 21.9 0.200
Atrial fibrillation (%) 8.4 9.1 0.424
HCM (%) 1.7 3.4 0.121
Anti-platelet (%) 49.0 54.3 0.073
Statins (%) 59.1 66.9 0.013
ACEI (%) 22.0 22.0 0.534
ARB (%) 49.7 46.0 0.165
Beta-blocker (%) 59.4 66.4 0.023
Alpha-blocker (%) 6.6 6.4 0.500
CCB (%) 55.2 57.1 0.324
Diuretic (%) 16.1 18.7 0.192
Warfarin (%) 6.6 7.2 0.448
Denote: BUN blood uria nitrogen, LDL-C low-density lipoprotein cholesterol,
HDL-C high-density lipoprotein cholesterol, CHD coronary heart disease,
HCM hypertrophy cardiomyopahty, ACEI angiotensin converting enzyme
inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
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covariates, only age was still positively correlated with
OSA (OR: 1.071, 95% CI: 1.029–1.116, P = 0.001).
Discussion
In our cross-sectional study of randomly selected hyper-
tensive patients, the prevalence of OSA was 70.5%, with
a predilection for males versus females (78.4% versus
21.6%). Compared to those without OSA, subjects with
OSA had higher cardiovascular risk profiles, with the
highest risk in those with more severe OSA. Age, BMI,
HbA1c, IVS, LVPW, statins, and beta-blockers were
positively associated with OSA while HDL-C was nega-
tively associated with OSA in univariate regression
analysis. After multivariate regression analyses, with
Table 2 Comparisons between different OSA groups
Variables Without OSA Mild Moderate-severe P value
N (%) 286 (29.5) 318 (32.7) 367 (37.8)
Age (years) 56.5 ± 13.3 59.9 ± 11.4 58.8 ± 11.9 0.002
Male (%) 71.7 73.6 82.6 <0.001
BMI (Kg/m2) 24.6 ± 3.6 24.8 ± 3.4 26.6 ± 4.4 <0.001
SBP (mm Hg) 137.3 ± 20.4 137.7 ± 21.5 137.1 ± 21.5 0.934
DBP (mm Hg) 79.3 ± 13.6 79.3 ± 14.8 79.4 ± 14.0 0.985
AHI 1.7 ± 1.4 9.2 ± 2.7 33.1 ± 15.7 <0.001
IVS (mm) 10.7 ± 1.8 11.2 ± 2.6 11.5 ± 2.1 <0.001
LVPW (mm) 10.2 ± 1.8 10.3 ± 1.7 10.7 ± 1.9 0.001
HbA1c (%) 6.1 ± 1.1 6.2 ± 1.1 6.2 ± 1.2 0.838
Creatinine (μmol/L) 91.6 ± 48.0 92.7 ± 45.3 104.5 ± 79.2 0.012
BUN (mmol/L) 5.5 ± 3.2 5.7 ± 2.9 5.9 ± 2.8 0.290
FPG (mmol/L) 6.2 ± 2.6 6.3 ± 2.5 6.6 ± 3.4 0.097
Triglyceride (mmol/L) 1.9 ± 0.3 1.7 ± 0.1 1.9 ± 0.1 0.665
Total cholesterol (mmol/L) 4.5 ± 1.3 4.5 ± 1.3 4.6 ± 1.2 0.442
LDL-C (mmol/L) 2.7 ± 1.0 2.7 ± 1.0 2.7 ± 1.0 0.938
HDL-C (mmol/L) 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.2 0.892
Proteinuria (%) 17.1 18.5 22.0 0.027
Diabetes mellitus (%) 19.6 23.0 25.6 0.038
Dyslipidemia (%) 10.5 14.2 15.0 0.057
Aortic dissection (%) 20.3 20.8 19.1 0.358
Aneurysm (%) 4.5 4.7 6.0 0.221
CHD (%) 37.4 39.9 43.6 0.058
Cerebrovascular disease (%) 6.6 11.0 9.0 0.195
Heart failure (%) 19.2 17.6 25.6 0.019
Atrial fibrillation (%) 8.4 10.1 8.2 0.462
HCM (%) 1.7 3.1 3.5 0.112
Anti-platelet (%) 49.0 53.1 55.3 0.060
Statins (%) 59.1 68.2 65.7 0.057
ACEI (%) 22.0 22.0 22.1 0.514
ARB (%) 49.7 45.3 46.6 0.249
Beta-blocker (%) 59.4 62.9 69.5 0.004
Alpha-blocker (%) 6.6 6.3 6.5 0.514
CCB (%) 55.2 58.5 55.9 0.478
Diuretic (%) 16.1 16.7 20.4 0.076
Warfarin (%) 2.0 2.5 2.6 0.512
Denote: BUN blood uria nitrogen, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CHD coronary heart disease, HCM hypertrophy
cardiomyopahty, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
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extensively adjusting for potential covariates, only BMI
remained significantly associated with OSA in male sub-
jects, while in females, only age remained significantly
associated with OSA. Thus there are significant and
important differences in epidemiological characteristics
between Chinese male and female OSA patients.
Recent epidemiological studies reveal a high preva-
lence of OSA in the general population [11–13]. OSA is
a major public health problem worldwide owing to its
close relationship with a variety of CVD such as hyper-
tension [14], diabetes mellitus [15], coronary heart dis-
ease [16], cerebrovascular disease [17], atrial fibrillation
[18] and congestive heart failure [19]. Mechanistically,
subjects with OSA suffer continuous sympathetic nerve
and renin-angiotensin axis activation, oxidative stress
and systemic inflammation, and all of these pathological
alterations are detrimental to cardiac and vascular sys-
tems [4, 20, 21]. Results from our present study further
confirmed previous findings. In our study, compared to
hypertensive patients without OSA, those with OSA
were older and had higher values of BMI, cardiac struc-
tural changes, and HbA1c (P < 0.05 for all comparisons).
Furthermore, the incidences of co-morbidities including
proteinuria, diabetes mellitus, dyslipidemia, aneurysm,
coronary heart disease, cerebrovascular disease, heart
failure, atrial fibrillation and hypertrophy cardiomyop-
athy were also marginally higher in OSA patients than
those without OSA, although without statistical sig-
nificance. All these findings strongly indicated that
hypertensive patients with OSA are at increased cardio-
vascular risk profiles than their counterparts without
Table 3 Comparisons between male and female OSA patients
Variables Female Male P value
N (%) 148 (21.6) 537 (78.4)* <0.001
Age (years) 62.8 ± 10.2 58.4 ± 11.9* <0.001
BMI (Kg/m2) 26.2 ± 4.2 25.6 ± 4.1 0.136
SBP (mm Hg) 139.8 ± 21.4 136.7 ± 21.5 0.111
DBP (mm Hg) 79.1 ± 15.1 79.4 ± 14.1 0.831
AHI 18.0 ± 15.4 23.1 ± 16.8* 0.001
IVS (mm) 10.7 ± 1.8 11.6 ± 2.4* <0.001
LVPW (mm) 9.9 ± 1.6 10.7 ± 1.8* <0.001
HbA1c (%) 6.6 ± 1.4 6.2 ± 1.1* 0.001
Creatinine (μmol/L) 81.7 ± 38.7 103.7 ± 52.2* <0.001
BUN (mmol/L) 5.7 ± 3.5 5.8 ± 2.6 0.836
FPG (mmol/L) 7.0 ± 3.4 6.3 ± 2.8* 0.015
Triglyceride (mmol/L) 1.8 ± 0.2 1.8 ± 0.3 0.619
Total cholesterol (mmol/L) 4.7 ± 1.4 4.5 ± 1.2* 0.019
LDL-C (mmol/L) 2.8 ± 1.1 2.7 ± 0.9 0.092
HDL-C (mmol/L) 1.1 ± 0.3 1.0 ± 0.2 0.947
Proteinuria (%) 14.9 21.9 0.289
Diabetes mellitus (%) 33.8 21.8* 0.003
Dyslipidemia (%) 23.0 12.3* 0.001
Aortic dissection (%) 10.8 22.3* 0.002
Aneurysm (%) 1.4 6.5* 0.014
CHD (%) 37.8 43.0 0.258
Cerebrovascular disease (%) 12.8 9.1 0.181
Heart failure (%) 25.0 21.0 0.303
Atrial fibrillation (%) 12.8 8.0 0.070
HCM (%) 4.1 3.2 0.595
Anti-platelet (%) 55.4 54.0 0.762
Statins (%) 68.2 66.5 0.687
ACEI (%) 19.6 22.7 0.417
ARB (%) 43.2 46.7 0.450
Beta-blocker (%) 60.8 68.0 0.102
Alpha-blocker (%) 3.4 7.3 0.088
CCB (%) 60.8 56.1 0.300
Diuretic (%) 18.9 18.6 0.935
Warfarin (%) 10.1 6.3 0.112
Denote: BUN blood uria nitrogen, LDL-C low-density lipoprotein cholesterol,
HDL-C high-density lipoprotein cholesterol, CHD coronary heart disease,
HCM hypertrophy cardiomyopahty, ACEI angiotensin converting enzyme
inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
*P < 0.05 versus female group
Table 4 Univariate regression analysis
Variables Odds ratio 95% confidence interval P value
Age 1.019 1.008–1.031 0.001
BMI 1.080 1.039–1.123 <0.001
HbA1c 1.174 1.015–1.358 0.031
HDL-C 0.398 0.232–0.682 0.001
IVS 1.181 1.008–1.283 <0.001
LVPW 1.121 1.032–1.219 0.007
Statins 1.397 1.051–1.856 0.021
Beta-blocker 1.350 1.016–1.794 0.039
Table 5 Multivariate regression analyses in male OSA subjects
Variables Odds ratio 95% confidence interval P value
Model 1
Age 1.022 1.006–1.073 0.006
BMI 1.081 1.031–1.133 0.001
Model 2
Age 1.019 1.001–1.038 0.035
BMI 1.066 1.01–1.125 0.02
Model 3
BMI 1.064 1.008–1.123 0.024
Model 1 was adjusted to SBP and DBP
Model 2 was adjusted to SBP, DBP, DM, Dyslipidemia, FBG, HbA1c, LDL-C
and HDL-C
Model 3 was adjusted to SBP, DBP, DM, Dyslipidemia, FBG, HbA1c, LDL-C,
HDL-C, Statins, Diuretics and Beta-blocker
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OSA. The higher percentage of statin and beta-blockers
usage in OSA patients might be due to much more mor-
bidities in these populations which required correspond-
ing drugs treatment. Further evaluation and comparison
between different degrees of OSA groups showed that
there was a dose-effect relationship between OSA and
cardiovascular risk (as shown in Table 2) which was con-
sistent with previous reports [13, 22, 23]. Collectively,
these findings strongly indicated that hypertension and
OSA might confer addictive effects on cardiovascular
system and OSA increased risk of CVD in patients with
hypertension.
Compared to females, males were reportedly prone to
develop OSA owing to gender-specific differences in
upper-airway anatomy and function, fat distribution,
hormonal status and ventilatory control [24–26]. Indeed,
in our present cross-sectional study, we also observed
that in randomly selected hypertensive populations, the
percentage of male with OSA was nearly 3-folds higher
than females (78.4% versus 21.6%, P < 0.001), which was
similar to previous reports [27, 28]. With regard to trad-
itional risk factors for OSA, no significant differences in
systolic and diastolic blood pressure, BMI, FPG and lipid
profiles were observed between male and female OSA
patients. In contrast, female subjects were significantly
older than the males (62.8 ± 10.2 years versus 58.4 ±
11.9 years, P < 0.001). With respect to a higher percent-
age of male subjects with OSA, we considered that male
subjects in present study might have a higher prevalence
of undetected major risk factors for OSA such as smok-
ing, alcohol abuse and large neck girth, and our ongoing
study will include these risk factors so as to demonstrate
our hypothesis. In addition, relative small sample size
might not be powerful to differentiate these differences,
and further studies are warranted to clarify our postu-
lates. Of note, the rates of proteinuria, aortic dissection,
aneurysm and coronary heart disease were slightly
higher in males, and the rates of diabetes mellitus, dys-
lipidemia, cerebrovascular disease, heart failure and
atrial fibrillation were marginally higher in females, sug-
gesting that there were somewhat differences in epi-
demiological characteristics between male and female
OSA patients.
After extensively adjusting for potential covariates,
only BMI remained significantly associated with OSA in
males, and age remained an independent contributor to
OSA in females. These gender-specific differences in in-
dependent risk factors associated with OSA suggest that
weight control in males, and modifying age-related
pathophysiological alterations such as estrogen and pro-
gesterone depletion in females, conceivably may be rele-
vant to mitigating OSA in Chinese hypertensive patients.
Our study has several limitations. First our results can
only be used for hypothesis–generation, owing to the in-
herent limitations of cross-sectional research. Second,
the relative small sample size might not be adequately
powered to identify other significant differences in char-
acteristics between male and female OSA patients.
Third, some important risk factors for OSA, including
smoking status, alcohol consumption, neck girth and
hormone status, were not evaluated in the present study.
Last, we recorded only one blood pressure during ad-
mission. Twenty-four hour ambulatory blood pressure
monitoring may help better understand the additive ef-
fects of OSA and hypertension patterns on cardiovascu-
lar systems.
Conclusion
In our Chinese subjects, the likelihood of OSA in ran-
domly selected hypertensive patients is strikingly and
unexpectedly high, especially in males. Hypertensive
subjects with OSA have more cardiovascular risk factors
than those without OSA. Important differences are evi-
dent in male and female OSA patients. Large cohorts
and interventional studies are warranted to investigate
effective and efficient diagnostic and therapeutic strat-
egies for hypertensive patients with OSA.
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